Akums Drugs & Pharmaceuticals Ltd - Stock Valuation and Financial Performance

BSE: 544222 | NSE: AKUMS | Pharmaceuticals & Drugs | Small Cap

Akums Drugs & Pharmaceuticals Share Price

587.10 -8.40 -1.41%
as on 13-Dec'24 14:19

DeciZen - make an informed investing decision on Akums Drugs & Pharmaceuticals

Overall Rating
Bole Toh

1. Quality

2. Valuation

Overvalued

3. Price Trend

Akums Drugs & Pharmaceuticals stock performance -

mw4me loader
P/E Ratio (SA):
74.73
Market Cap:
9,372.8 Cr.
52-wk low:
527
52-wk high:
1,174.9

Is Akums Drugs & Pharmaceuticals Ltd an attractive stock to invest in?

1. Is Akums Drugs & Pharmaceuticals Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Akums Drugs & Pharmaceuticals Ltd is a good quality company.

2. Is Akums Drugs & Pharmaceuticals Ltd undervalued or overvalued?

The key valuation ratios of Akums Drugs & Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Akums Drugs & Pharmaceuticals Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Akums Drugs & Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Akums Drugs & Pharmaceuticals:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Akums Drugs & Pharmaceuticals Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 25.8%19.2%8.5%6.6%13.8%13.7%9.8%-29.1%-73.8%42.8%-
Value Creation
Index
0.90.4-0.4-0.50.00.0-0.3-3.2-6.52.2-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 8979675646285966837378371,1621,2871,287
Sales YoY Gr.-7.8%-41.6%11.3%-5.2%14.7%7.9%13.6%38.8%10.7%-
Adj EPS 8.26.63.62.55.25.73.62-27.115.48
YoY Gr.--19.7%-45.7%-30.3%111.3%9%-37.8%-42.5%-1427%NA-
BVPS (₹) 41.648.151.554.159.465.149.839.61321.80
Adj Net
Profit
10684.746.132.167.773.950.829.2-387220125
Cash Flow from Ops. 291683.444.171.42.8-21.855.622894-
Debt/CF from Ops. 4.60.6181.30.518.2-1.70.40.51.6-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 4.1%16.7%20.4%10.7%
Adj EPS 7.3%24%63%NA
BVPS-6.9%-18.2%-24.1%67.9%
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
21.814.67.24.79.29.26.54.6-102.988.473.2
Op. Profit
Mgn %
15.812.47.64.712.6125.43.2-31.218.3-0.8
Net Profit
Mgn %
11.88.88.25.111.410.86.93.5-33.317.19.8
Debt to
Equity
0.30.20.10.100.10.100.70.50
Working Cap
Days
19622238634640640745841735540477
Cash Conv.
Cycle
737411710292889382625950

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 73.20%

Sales growth is growing at healthy rate in last 3 years 20.42%

Sales growth is not so good in last 4 quarters at -6.50%

Latest Financials - Akums Drugs & Pharmaceuticals Ltd.

Standalone Consolidated
TTM EPS (₹) 8 -0.3
TTM Sales (₹ Cr.) 1,287 4,178
BVPS (₹.) 0 180.1
Reserves (₹ Cr.) 2,204 2,803
P/BV 0.00 3.31
PE 74.73 0.00
From the Market
52 Week Low / High (₹) 527.00 / 1174.85
All Time Low / High (₹) 527.00 / 1174.85
Market Cap (₹ Cr.) 9,373
Equity (₹ Cr.) 31.5
Face Value (₹) 2
Industry PE 44

Management X-Ray of Akums Drugs & Pharmaceuticals:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Akums Drugs & Pharmaceuticals

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales8979675646285966837378371,1621,287
Operating Expenses 7558475225995216016978111,5241,051
Manufacturing Costs32414247394458517284
Material Costs609674357428360418466524768788
Employee Cost 9211010210094103124123136147
Other Costs 2323212427364911354831
Operating Profit 142120432975824027-362236
Operating Profit Margin (%) 15.8%12.4%7.6%4.7%12.6%12.0%5.4%3.2%-31.2%18.3%
Other Income 213844435557665558102
Interest 814853441413
Depreciation 14242224232325262830
Exceptional Items 00-30000-2490-145
Profit Before Tax 141119544310511276-195-335150
Tax 35351011373725-504725
Profit After Tax 106854432687551-145-382125
PAT Margin (%) 11.8%8.8%7.8%5.2%11.4%11.0%6.9%-17.4%-32.9%9.7%
Adjusted EPS (₹)8.26.63.42.55.25.83.6-10.2-26.78.8
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 537622666699767842712567186312
Share Capital 111111111429
Reserves 536621665698766841711566171283
Minority Interest0000000000
Debt12694504733513623122142
Long Term Debt2241200000022
Short Term Debt12570384733513623122121
Trade Payables111574143866910890252178
Others Liabilities 7793927174855705851,2541,259
Total Liabilities 8518678498609601,0461,4261,2651,8141,891

Fixed Assets

Gross Block324322335353367389417442470513
Accumulated Depreciation6584104126147169191213237260
Net Fixed Assets260237231227219220226229233253
CWIP 00000011116
Investments 442221212081149141139
Inventories161921208812110612396179197
Trade Receivables191143116120121159178212304256
Cash Equivalents 2122304721269
Others Assets2143893574014775377455769301,020
Total Assets 8518678498609601,0461,4261,2651,8141,891

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 29168344713-225622894
PBT 141119544310511276-195-335150
Adjustment 79-8-9-17-25-26-19-12-19
Changes in Working Capital -8955-14194-49-23-28100-82
Tax Paid -30-16-28-8-19-33-46-5-7-30
Cash Flow From Investing Activity -81-14144-35-46-15-242-100-298-202
Capex -13-1-34-18-15-23-31-29-28-103
Net Investments 0000010-1900
Others -68-13978-17-317-211-52-270-99
Cash Flow From Financing Activity 69-44-47-8-281530239590
Net Proceeds from Shares 000000320000
Net Proceeds from Borrowing 000-12000000
Interest Paid 0-14-8000-2-1-2-11
Dividend Paid 0000000000
Others 69-30-394-2815-16397101
Net Cash Flow 17-1701-2338-4225-18
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)21.8314.616.834.759.249.36.54-22.73-101.4650.47
ROCE (%)25.7519.188.56.5713.8313.699.77-29.06-73.8342.75
Asset Turnover Ratio1.181.130.660.740.660.680.60.620.750.69
PAT to CFO Conversion(x)0.271.980.071.381.040.04-0.43N/AN/A0.75
Working Capital Days
Receivable Days71638368747583858179
Inventory Days55486860646157484353
Payable Days664650366567696981100

Akums Drugs & Pharmaceuticals Ltd Stock News

Akums Drugs & Pharmaceuticals Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Akums Drugs & Pharmaceuticals on 13-Dec-2024 14:19 is ₹587.1.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 13-Dec-2024 14:19 the market cap of Akums Drugs & Pharmaceuticals stood at ₹9,372.8.
The latest P/E ratio of Akums Drugs & Pharmaceuticals as of 13-Dec-2024 14:19 is 74.73.
The latest P/B ratio of Akums Drugs & Pharmaceuticals as of 13-Dec-2024 14:19 is 0.00.
The 52-week high of Akums Drugs & Pharmaceuticals is ₹1,174.9 and the 52-week low is ₹527.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Akums Drugs & Pharmaceuticals is ₹1,287 ( Cr.) .

About Akums Drugs & Pharmaceuticals Ltd

The company was incorporated as a public company, limited by shares, under the Companies Act, 1956, as amended, in the name of ‘Akums Drugs and Pharmaceuticals Limited’, pursuant to a certificate of incorporation dated April 19, 2004 issued by the Registrar of Companies, Delhi and Haryana in New Delhi (RoC). The company received a certificate of commencement of business issued by the RoC dated May 13, 2004. 

Established in 2004,  Akums Drugs and Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. As one of the leading CDMOs in India, the company owns the intellectual property for the manufacturing processes of several of its formulations, and its core business is focused on providing end-to-end product development and manufacturing solutions to its clients. Some of its other services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and global markets, and other testing services. In addition to its core CDMO business, it is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs).

Business area of the company 

As a CDMO, the company produces an extensive range of dosage forms including tablets, capsules, liquid orals, vials, ampoules, blow-filled seals, topical preparations, eye drops, dry powder injections, and gummies, among others. It also engages in the marketing of trade generic and products under its own brand through distributors and alternative channels across India.  

Key Awards and accreditations

  • 2018: Received India Pharma Leader Award by Government of India.
  • 2019: Received India Pharma Leader Award by Government of India.
  • 2021: Award for India Pharma Award for Excellence in Contract Research and Manufacturing by Informamarkets. 
  • 2022: Award for Excellence in R&D and Innovation by ET Ascent.
  • 2022: Awarded the International Healthcare award as Pharmaceutical Company of the Year in contract manufacturing by Times Cyber Media.
  • 2022: Awarded the Excellence in Operations – Manufacturing by CPHI Awards.
  • 2022: Awarded Asia’s Pharma Excellence Awards in Innovation in Nutraceutical, Cosmetic and Wellness Award by CMO Asia.
  • 2023: Awarded Dream Employer of the Year by Times Ascent.
  • 2023: Awarded the Excellence Award in Nutraceutical category by IHW Council.
  • 2023: Award for the best brand based in North India by Exchange4Media. 
  • 2023: Awarded the best Technology Adaption – Cash Management Services by HDFC Bank.
  • 2023: Awarded 2nd Runner up in Best Trademarks portfolio by CII Industrial Intellectual Property Awards. 
  • 2023: Awarded the Excellence in Formulations by India Pharma World Awards, The Economic Times. 
  • 2023: Awarded the Most Admired Quality Pharmaceutical Manufacturer of India 2023 by Observe Now. 
  • 2023: Awarded the Certificate of Appreciation for Excellence in Innovative Formulations – Nutraceutical and Wellness Award by Food Safety and Nutrition Summit and Awards 2023.

Major events and milestones

  • 2004: Incorporation of the company.
  • 2004: Established first plant for oral dosage commissioned at 19, 20, 21, sector 6A, Haridwar, Uttarakhand. 
  • 2007: Established dedicated manufacturing site for oral liquid dosage at 22, Sector 6A, Sidcul, Haridwar, Uttarakhand and sterile products at 2,3,4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand.
  • 2009: Incorporated Maxcure Nutravedics Limited to venture into nutraceuticals.
  • 2010: Dedicated a facility for hormones at 48, Sector 6A, SIDCUL, Haridwar, Uttarakhand.
  • 2010: Dedicated a facility for cosmetics and dermatology at 47, Sector 6A, SIDCUL, Haridwar, Uttarakhand.
  • 2010: Incorporated Akumentis Healthcare Limited to venture into branded formulations.
  • 2011: Innovated bi-layered sustained release tablets for the first time.
  • 2012: Acquired Pure and Cure Healthcare Private Limited to expand capacity and capabilities.
  • 2013: Innovated tablet-in-tablet sustained release tablets for the first time.
  • 2013: Acquired Malik Lifesciences Private Limited manufacturing sites to expand capacity and capabilities.
  • 2013: Expanded into the African market.
  • 2015: Expanded into the Asian market.
  • 2015: Established research and development laboratory in Mumbai, Maharashtra to venture into regulated market.
  • 2016: Maxcure Nutravedics Limited received US-NSF certification.
  • 2019: Investment by Ruby QC Investment Holdings Pte. Ltd. in the company to become a minority shareholder.
  • 2021: Acquired Parabolic Drugs to form Akums Lifesciences Limited and ventured into APIs.
  • 2021: Acquisition of a facility at Kotdwar, Uttarakhand by Akums Healthcare Limited.
  • 2022: Plant at 19, 20, 21, Sector 6A, SIDCUL, Haridwar, Uttarakhand and plant at 2, 3, 4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand accredited European Union-Good Manufacturing Practices, qualifying for exports to European markets.
  • 2022: Acquisition of a facility in Haridwar, Uttarakhand by Akums Healthcare Limited and a facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited.
  • 2023: Acquisition of another facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited.
  • 2023: Merger of Akums Lifesciences Limited with Pure and Cure Healthcare Private Limited.


Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.